Predictors of Duloxetine versus Other Treatments among Veterans with Diabetic Peripheral Neuropathic Pain: A Retrospective Study

Pain Practice

Volumn 12, Issue 5, 2012, Pages 366-373

  Zhao, Yingnan ^a,b   Liu, Jinan ^a,b   Zhao, Yang ^c   Thethi, Tina ^a,d   Fonseca, Vivian ^d   Shi, Lizheng ^a,b,d  

^a TULANE UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressive agents; Diabetic neuropathy; Diabetic peripheral; Neuropathic pain; Veterans

Indexed keywords

DULOXETINE; GABAPENTIN; PREGABALIN; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ANXIETY DISORDER; ARTICLE; CEREBROVASCULAR DISEASE; DIABETIC PERIPHERAL NEUROPATHIC PAIN; DIABETIC PERIPHERAL NEURPATHIC PAIN; DISEASE SEVERITY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPATHIC PAIN; PAIN ASSESSMENT; PRESCRIPTION; RETROSPECTIVE STUDY; SELF REPORT; SUBSTANCE ABUSE; VETERAN;

EID: 84861939768     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/j.1533-2500.2011.00494.x     Document Type: Article

References (44)

1. Sternberg TL. Diabetes peripheral neuropathy: current concepts and treatment. Northeast Florida Med. 2005;Spring:4.
2. Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population >=40years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care. 2004;27:1591-1597.
3. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29:1518-1522.
4. Daousi C, MacFarlane IA, Woodward A, Nurmikko TJ, Bundred PE, Benbow SJ. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med. 2004;21:976-982.
5. Barrett AM, Lucero MA, Le T, Robinson RL, Dworkin RH, Chappell AS. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. 2007;8(suppl 2):S50-S62.
6. Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm. 2004;61:160-173; quiz 175-166.
7. Jensen TS, Backonja MM, Hernandez Jimenez S, Tesfaye S, Valensi P, Ziegler D. New perspectives on the management of diabetic peripheral neuropathic pain. Diab Vasc Dis Res. 2006;3:108-119.
8. Koopman RJ, Mainous AG III, Liszka HA, et al. Evidence of nephropathy and peripheral neuropathy in US adults with undiagnosed diabetes. Ann Fam Med. 2006;4:427-432.
9. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract. 2008;8:45-56.
10. Benbow SJ, Wallymahmed ME, MacFarlane IA. Diabetic peripheral neuropathy and quality of life. Q J Med. 1998;91:733-737.
11. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123-128.
12. Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD. Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complications. 2007;21:306-314.
13. Cole BE. Diabetic peripheral neuropathic pain: recognition and management. Pain Med. 2007;8(suppl 2):S27-S32.
14. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients' perspectives. J Pain. 2006;7:892-900.
15. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31(suppl 1):S12-S54.
16. Argoff CE, Cole BE, Fishbain DA, Irving GA. Diabetic peripheral neuropathic pain: clinical and quality-of-life issues. Mayo Clin Proc. 2006;81:S3-S11.
17. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85:S3-S14.
18. O'Connor AB, Dworkin RH. Treatment of Neuropathic Pain: an Overview of Recent Guidelines. Am J Med. 2009;122:S22-S32.
19. Vadalouca A, Siafaka I, Argyra E, Vrachnou EVI, Moka E. Therapeutic Management of Chronic Neuropathic Pain. Ann NY Acad Sci. 2006;1088:164-186.
20. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006;81:S12-S25.
21. Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116:109-118.
22. Raskin J, Pritchett YL, Wang F, et al. A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain. Pain Med. 2005;6:346-356.
23. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med. 2006;7:373-385.
24. Wernicke J, Lledo A, Raskin J, Kajdasz DK, Wang F. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf. 2007;30:437-455.
25. Wernicke JF, Pritchett YL, D'Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67:1411-1420.
26. Wernicke JF, Wang F, Pritchett YL, et al. An open-label 52-week clinical extension comparing duloxetine with routine care in patients with diabetic peripheral neuropathic pain. Pain Med. 2007;8:503-513.
27. Freynhagen R, Strojek K, Griesing T, Whalen E, Balkenohl M. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain. 2005;115:254-263.
28. Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104-2110.
29. Richter RW, Portenoy R, Sharma U, Lamoreaux L, Bockbrader H, Knapp LE. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253-260.
30. Stacey BR, Dworkin RH, Murphy K, Sharma U, Emir B, Griesing T. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med. 2008;9:1202-1208.
31. Tolle T, Freynhagen R, Versavel M, Trostmann U, Young JP Jr. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203-213.
32. Wu EQ, Birnbaum HG, Mareva MN, et al. Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain. J Pain. 2006;7:399-407.
33. O'Connor AB, Noyes K, Holloway RG. A Cost-Utility Comparison of Four First-Line Medications in Painful Diabetic Neuropathy. Pharmacoeconomics. 2008;26:1045-1064.
34. O'Connor AB. Neuropathic Pain: quality-of-Life Impact, Costs and Cost Effectiveness of Therapy. Pharmacoeconomics. 2009;27:95-112.
35. Zhao Y, Sun P, Watson P. Medication Compliance and Healthcare Costs among Patients with Diabetic Peripheral Neuropathic Pain Initiating Duloxetine versus Pregabalin. Curr Med Res Opin. 2011;27:785-792.
36. Wu N, Chen SY, Hallett LA, et al. Opioid Utilization and Health-Care Costs among Patients with Diabetic Peripheral Neuropathic Pain Treated with Duloxetine vs. Other Therapies. Pain Pract. 2011;11:48-56.
37. Blumenthal D, Herdman R. Editors; VA Pharmacy Formulary Analysis Committee, Division of Health Care Services. Vol. 2010.
38. Criteria for Nonformulary Use of Duloxetine in Painful Diabetic Neuropathy. In: Panel VPBMSHGatMA, ed., Vol. 2011.
39. Palos GR, Mendoza TR, Mobley GM, Cantor SB, Cleeland CS. Asking the community about cutpoints used to describe mild, moderate, and severe pain. J Pain. 2006;7:49-56.
40. Sullivan MD, Edlund MJ, Fan MY, Devries A, Brennan Braden J, Martin BC. Trends in use of opioids for non-cancer pain conditions 2000-2005 in commercial and Medicaid insurance plans: the TROUP study. Pain. 2008;138:440-449.
41. Zhao Y, Ye W, Boye KS, Holcombe JH, Hall JA, Swindle R. Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy. J Diabetes Complications. 2010;24:9-19.
42. Gore M, Brandenburg NA, Dukes E, Hoffman DL, Tai K-S, Stacey B. Pain Severity in Diabetic Peripheral Neuropathy is Associated with Patient Functioning, Symptom Levels of Anxiety and Depression, and Sleep. J Pain Symptom Manage. 2005;30:374-385.
43. Boulanger L, Zhao Y, Foster TS, Fraser K, Bledsoe SL, Russell MW. Impact of comorbid depression or anxiety on patterns of treatment and economic outcomes among patients with diabetic peripheral neuropathic pain*. Curr Med Res Opin. 2009;25:1763-1773.
44. Quilici S, Chancellor J, Lothgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6.